T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib).

Authors:
Geling Li
Geling Li
Walther Oncology Center
Emily Waite
Emily Waite
The University of Alabama at Birmingham
Julie Wolfson
Julie Wolfson
Childrens Hospital Los Angeles
United States

Blood Adv 2017 Dec 18;1(27):2724-2728. Epub 2017 Dec 18.

Institute for Cancer Outcomes and Survivorship, School of Medicine, University of Alabama at Birmingham, Birmingham, AL.

A 19-year-old ataxia-telangiectasia patient with T-cell prolymphocytic leukemia harbored 2 -activating hotspot mutations.The patient suffered toxicities with chemotherapy, but demonstrated a clinical response to novel use of a JAK3 inhibitor (tofacitinib).

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2017010470DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745136PMC

Still can't find the full text of the article?

Let us try to send a request to the authors directly.
December 2017
6 Reads

Publication Analysis

Top Keywords

jak3 inhibitor
8
prolymphocytic leukemia
8
inhibitor tofacitinib
8
t-cell prolymphocytic
8
-activating hotspot
4
hotspot mutationsthe
4
harbored -activating
4
ataxia-telangiectasia patient
4
leukemia harbored
4
mutationsthe patient
4
suffered toxicities
4
clinical response
4
response novel
4
novel jak3
4
demonstrated clinical
4
chemotherapy demonstrated
4
19-year-old ataxia-telangiectasia
4
toxicities chemotherapy
4
patient suffered
4
patient t-cell
4

References

(Supplied by CrossRef)
Inactivation of the ATM gene in T-cell prolymphocytic leukemias
Stoppa-Lyonnet et al.
Blood 1998
Leukemia and lymphoma in ataxia telangiectasia
Taylor et al.
Blood 1996

Similar Publications